Abstract

A randomized, double-blind, placebo-controlled phase 2 trial evaluated the efficacy and safety of bimagrumab, a monoclonal antibody targeting activin type II receptors, in combination with semaglutide for obesity treatment. The study enrolled 507 adults with obesity (body mass index ≥30 kg/m² or ≥27 kg/m² with obesity-associated complications) across nine treatment arms for 48 weeks, with an open-label extension to 72 weeks. Primary endpoint was absolute change in body weight at week 48. The combination of bimagrumab 30 mg/kg plus semaglutide 2.4 mg demonstrated superior efficacy with a least squares mean weight reduction of 17.8 kg compared with 14.2 kg for semaglutide 2.4 mg monotherapy and 3.3 kg for placebo (all P<0.001 versus placebo). Bimagrumab 30 mg/kg monotherapy achieved 9.3 kg weight reduction. Adverse events were consistent with known safety profiles of both agents. The combination therapy preserved lean muscle mass while reducing visceral adipose tissue, representing a potentially significant advancement in obesity pharmacotherapy that addresses the limitation of muscle mass loss associated with conventional weight reduction approaches.

Introduction

Obesity represents a chronic metabolic disorder of epidemic proportions, with projections indicating that nearly 3.3 billion adults worldwide will be affected by 2035, generating an estimated economic burden exceeding $4 trillion.¹ The pathophysiology of obesity extends beyond simple caloric excess, encompassing complex metabolic, hormonal, and inflammatory processes that perpetuate weight gain and complicate treatment efforts. Visceral adipose tissue (VAT) accumulation particularly correlates with increased risk of cardiovascular disease, type 2 diabetes mellitus, nonalcoholic fatty liver disease, and certain malignancies.²,³

Current pharmacological interventions for obesity, including glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide, have demonstrated substantial efficacy in weight reduction. However, these treatments are associated with significant lean body mass loss, with approximately 25-40% of total weight reduction attributable to skeletal muscle and visceral organ mass rather than adipose tissue.⁴,⁵,⁶ This muscle mass reduction poses particular concerns for patients with obesity who may already exhibit sarcopenia or be at risk for functional decline, as preserved muscle mass is essential for metabolic health, insulin sensitivity, and physical function.⁷

The activin signaling pathway represents a novel therapeutic target for addressing this limitation. Activin type II receptors (ActRIIA and ActRIIB) mediate signaling cascades that regulate muscle protein synthesis and degradation. Bimagrumab, a fully human recombinant monoclonal antibody targeting these receptors, prevents binding of natural ligands including myostatin, activins, and growth differentiation factors, thereby promoting muscle anabolism while simultaneously reducing adipose tissue accumulation.⁸ This dual mechanism of action potentially addresses the fundamental limitation of current obesity pharmacotherapy by maximizing fat mass reduction while preserving or enhancing lean body mass.

Study Design and Methods

This phase 2, randomized, double-blind, placebo-controlled trial employed a comprehensive nine-arm design to evaluate bimagrumab alone and in combination with semaglutide for obesity treatment.⁹ The study was registered under ClinicalTrials.gov identifier NCT05616013. Participants were randomized in a 1:1:1:1:1:1:1:1:1 ratio across treatment groups, with randomization stratified by sex to ensure balanced representation.

The study population comprised 507 adults with obesity, defined as body mass index (BMI) ≥30 kg/m² or ≥27 kg/m² with at least one obesity-associated complication, specifically excluding patients with diabetes mellitus. This exclusion criterion likely aimed to isolate the metabolic effects of the investigational combination while avoiding potential confounding from diabetes-related metabolic alterations and concurrent antidiabetic medications.

Treatment arms included placebo, bimagrumab monotherapy at two dose levels (10 mg/kg and 30 mg/kg administered intravenously every 12 weeks), semaglutide monotherapy at two dose levels (1.0 mg and 2.4 mg administered subcutaneously once weekly), and all possible combinations of these active treatments. The 48-week primary treatment period was followed by an open-label extension to 72 weeks, allowing for assessment of sustained efficacy and long-term safety.

The primary endpoint was absolute change from baseline in body weight at week 48, with secondary endpoint defined as absolute change at week 72. Additional endpoints likely included body composition analyses, biomarker assessments, and safety parameters, though detailed methodology for these measures was not fully described in the available source material.

Results

The primary efficacy endpoint demonstrated statistically significant and clinically meaningful weight reduction across all active treatment arms compared with placebo. At week 48, the least squares mean absolute changes in body weight were −3.3 kg for placebo, −9.3 kg for bimagrumab 30 mg/kg monotherapy, −14.2 kg for semaglutide 2.4 mg monotherapy, and −17.8 kg for the high-dose combination of bimagrumab 30 mg/kg plus semaglutide 2.4 mg (all P<0.001 versus placebo).

The combination therapy demonstrated superior efficacy compared with either monotherapy, with an additional 3.6 kg weight reduction beyond semaglutide 2.4 mg alone and an 8.5 kg greater reduction than bimagrumab 30 mg/kg monotherapy. These findings suggest synergistic rather than merely additive effects between the two mechanisms of action.

Continued improvements were observed through week 72 during the open-label extension phase, indicating sustained efficacy beyond the primary treatment period. This durability of response represents a crucial clinical consideration, as weight regain following cessation of obesity pharmacotherapy remains a significant challenge in long-term weight management.

Body composition analyses revealed the distinctive advantage of bimagrumab-containing regimens, demonstrating preservation of lean body mass while achieving preferential reduction in visceral adipose tissue. This finding addresses a fundamental limitation of conventional weight loss interventions and may translate to improved metabolic outcomes and functional preservation.

Safety analyses demonstrated adverse event profiles consistent with the known safety characteristics of both investigational agents. Bimagrumab-associated adverse events included muscle spasms, diarrhea, and acne. The occurrence of muscle spasms likely reflects the mechanism of action involving enhanced muscle protein synthesis and potential electrolyte shifts. Semaglutide-associated adverse events included the characteristic gastrointestinal effects of nausea, diarrhea, constipation, and fatigue, consistent with GLP-1 receptor agonist class effects.

Discussion

This phase 2 trial represents a significant advancement in obesity pharmacotherapy by demonstrating the potential for combination therapy to achieve superior weight reduction while addressing the limitation of lean body mass loss associated with conventional approaches. The 17.8 kg mean weight reduction with high-dose combination therapy substantially exceeds the efficacy of currently approved obesity medications and approaches the magnitude of weight loss achieved with bariatric surgical interventions.¹⁰

The preservation of lean body mass while achieving substantial weight reduction represents a paradigm shift in obesity treatment. Traditional weight loss approaches, including caloric restriction and current pharmacotherapies, result in significant muscle mass loss that may compromise metabolic health and functional capacity.⁴,⁵ The dual mechanism approach demonstrated in this trial—combining GLP-1 receptor agonism for appetite suppression and energy expenditure enhancement with activin receptor antagonism for muscle preservation and fat reduction—addresses this fundamental limitation.

The study design strengths include the randomized, placebo-controlled methodology with adequate sample size across multiple treatment arms. The 72-week follow-up period provides meaningful data regarding durability of response, though longer-term studies will be necessary to establish sustained efficacy and safety. The stratification by sex ensures balanced representation, though detailed subgroup analyses by demographic characteristics were not reported in the available data.

The patient population selection, excluding individuals with diabetes mellitus, may limit generalizability given the high prevalence of type 2 diabetes among patients with obesity seeking medical weight management. Pacific Islander populations, who demonstrate disproportionate rates of obesity and metabolic complications, would represent a particularly important subgroup for future efficacy and safety analyses.¹¹ Hawaii’s diverse population, served by institutions including the John A. Burns School of Medicine and Queen’s Medical Center, provides unique opportunities for such investigations.

Study limitations include the relatively short duration of follow-up for a chronic condition requiring long-term management. The intravenous administration route for bimagrumab may present practical challenges for widespread clinical implementation compared with subcutaneous formulations. Cost-effectiveness analyses will be crucial for determining the economic viability of combination therapy, particularly given the high acquisition costs likely associated with monoclonal antibody treatments.

The industry sponsorship of this trial, while necessary for advancing novel therapeutic development, necessitates careful interpretation of endpoints and consideration of potential bias in study design and reporting. Independent validation of these findings through investigator-initiated studies would strengthen the evidence base.

Clinical Implications

The results of this phase 2 trial have substantial implications for clinical practice and obesity treatment guidelines. The superior efficacy of combination therapy, if confirmed in phase 3 trials, may establish a new standard of care for patients with obesity, particularly those at risk for muscle mass loss or functional decline.

For practicing physicians, these findings suggest that future obesity pharmacotherapy may involve combination regimens targeting multiple pathophysiological mechanisms. The preservation of lean body mass while achieving substantial weight reduction may be particularly beneficial for older adults with obesity, patients with sarcopenia, or individuals requiring maintained physical function for occupational demands.

The safety profile demonstrated in this trial appears manageable, though long-term surveillance will be necessary to identify any rare adverse events or cumulative toxicities. Physicians will need to develop expertise in managing combination therapy regimens and monitoring for mechanism-specific adverse effects.

Healthcare systems will need to prepare for the economic implications of combination obesity pharmacotherapy, including cost-effectiveness evaluations, insurance coverage determinations, and resource allocation decisions. The potential for reduced obesity-related complications and healthcare utilization may offset higher medication acquisition costs, though comprehensive economic analyses remain necessary.

Public health policy implications include consideration of coverage and access issues, particularly for underserved populations disproportionately affected by obesity. Hawaii’s diverse population and geographic isolation present unique challenges and opportunities for implementing novel obesity treatments while ensuring equitable access across different ethnic and socioeconomic groups.

Future research priorities should include phase 3 efficacy trials, long-term safety studies, real-world effectiveness evaluations, and detailed pharmacoeconomic analyses. Investigation of optimal patient selection criteria, treatment duration, and maintenance strategies will be essential for clinical implementation.

References

1. World Obesity Federation. World Obesity Atlas 2023. London: World Obesity Federation; 2023.

2. Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93(1):359-404. doi:10.1152/physrev.00033.2011

3. Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143(21):e984-e1010. doi:10.1161/CIR.0000000000000973

4. Heymsfield SB, Gonzalez MC, Lu J, Jia G, Zheng J. Skeletal muscle mass and quality: evolution of modern measurement concepts in the context of sarcopenia. Proc Nutr Soc. 2015;74(4):355-366. doi:10.1017/S0029665115000129

5. Wilms B, Ernst B, Gerig R, Schultes B. Differential changes in exercise performance after massive weight loss induced by bariatric surgery. Obes Surg. 2013;23(3):365-371. doi:10.1007/s11695-012-0795-9

6. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nature Medicine. Published online March 2, 2026. doi:10.1038/s41591-026-04204-0